Influence of Bilateral Subthalamic Nucleus Deep Brain Stimulation on the Lipid Profile in Patients With Parkinson's Disease.

Subthalamic nucleus deep brain stimulation (STN-DBS) is a valuable alternative to pharmacotherapy alone in an advanced Parkinson's disease (PD). Given the growing number of patients with STN-DBS, its impact on the comorbidities should be considered. The aim of this study was to evaluate the influence of bilateral STN-DBS on the lipid profile in patients with PD. Three groups of parkinsonian patients were included: 20 treated pharmacologically-PHT group, 20 newly qualified for STN-DBS-DBS group, and 14 postoperative patients (median 30 months after surgery)-POP group. Plasma concentrations of the total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides (TG), and body weight were measured thrice in 9 ± 2 month intervals. A significant increase in the LDL-C concentration is observed early after surgery in the DBS group (11.4 mg/dl, < 0.01) followed by adverse changes in the HDL-C (-7.7 mg/dl, = 0.01) and TG (14.1 mg/dl, = 0.05) plasma levels. In the POP group, the average level of TC at the first visit was significantly higher ( < 0.01) than in the other groups and the TG level was higher than in the PHT group during the follow-up ( < 0.01). A strong positive correlation with body weight alteration after surgery was observed only for long-term changes in the TG levels. Our data indicate that STN-DBS may negatively affect the cardiometabolic profile of patients. Similarly to body weight gain, an increase in the LDL-C concentration occurred early after surgery while adverse changes in the HDL-C and TG plasma levels were more gradual.